Close

Recipharm bolsters biologics offering

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement

Sandoz has entered into a collaboration agreement with Shanghai...

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...
- Advertisement -

Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms.

The license, which applies to its facility in Wasserburg, Germany, also covers microbiological testing allowing Recipharm to insource bacterial endotoxin testing on its products, including testing diluent for one of the COVID-19 vaccines.

Kjell Johansson, President Manufacturing Services Europe said: “Vaccine manufacturing capacity and the associated testing is more crucial than ever, so we’re delighted to be able to further support our customers in the area.”

“The Recipharm team has extensive experience in handling products with aseptic requirements and this accreditation is just the latest step in ultimately bolstering our biologics offering for customers. This will allow us to not only to cater for requirements for the current pandemic, but also future requirements as we continue to see more biologics enter the drug pipeline.”

The new accreditation includes key biologic analytical techniques, including gel electrophoresis, UV/VIS spectrophotometers and osmometers, with plans to add more in 2021. In addition, the facility has also bolstered it packaging capabilities to support customers with clinical trial packaging.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement

Sandoz has entered into a collaboration agreement with Shanghai...

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »